SRC and head and neck squamous cell carcinoma: Importantly, we have shown significant response to the FAK inhibitor PF-562,271 alone, or the combination of BMS754807 and dasatinib in patient ex vivo human HNSCC tumors suggesting that potential exists for targeting FAK, IGF1R, and Src in HNSCC.